Increased Risk of Keratinocyte Carcinomas, Merkel Cell Carcinoma, and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor, Ruxolitinib.

Dababneh, Nadine Elias; Maazi, Mahan; Dababneh, Said; Popradi, Gizelle; Litvinov, Ivan V

Dababneh, Nadine Elias; Maazi, Mahan; Dababneh, Said; Popradi, Gizelle; Litvinov, Ivan V.

Afiliación

Dababneh NE; Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Maazi M; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Dababneh S; Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Popradi G; Division of Hematology, Department of Medicine, McGill University, Montreal, QC, Canada.
Litvinov IV; Division of Dermatology, Department of Medicine, McGill University, Montreal, QC, Canada.

J Cutan Med Surg ; : 12034754241258364, 2024 Jun 10.

Article en En | MEDLINE | ID: mdl-38859667

Palabras clave

JAK inhibitor; Merkel cell carcinoma (MCC); keratinocyte carcinomas; ruxolitinib; squamous cell carcinomas (SCCs)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Cutan Med Surg Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google